Latest RA CAPITAL MANAGEMENT, L.P. Stock Portfolio
RA CAPITAL MANAGEMENT, L.P. Performance:
2024 Q4: -9.3%YTD: 4.04%2023: -2.79%
Performance for 2024 Q4 is -9.3%, and YTD is 4.04%, and 2023 is -2.79%.
About RA CAPITAL MANAGEMENT, L.P. and 13F Hedge Fund Stock Holdings
RA CAPITAL MANAGEMENT, L.P. is a hedge fund based in BOSTON, MA. On 03-Apr-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $9.7 Billions. In it's latest 13F Holdings report, RA CAPITAL MANAGEMENT, L.P. reported an equity portfolio of $7.5 Billions as of 31 Dec, 2024.
The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , PCVX, JANX. The fund has invested 18.5% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 9.5% of portfolio in VAXCYTE INC.
The fund managers got completely rid off BIOGEN INC (BIIB), CG ONCOLOGY INC and NUVALENT INC-A (NUVL) stocks. They significantly reduced their stock positions in VERONA PHARMA PLC - ADR (VRNA), EVOLENT HEALTH INC - A (EVH) and REGULUS THERAPEUTICS INC (RGLS). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in SEPTERNA INC, SPDR S&P BIOTECH ETF (BIL) and 10X GENOMICS INC-CLASS A (TXG). The fund showed a lot of confidence in some stocks as they added substantially to SCILEX HOLDING CO, PROTARA THERAPEUTIC INC (TARA) and VOR BIOPHARMA INC (VOR).
The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , PCVX, JANX. The fund has invested 18.5% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 9.5% of portfolio in VAXCYTE INC.
The fund managers got completely rid off BIOGEN INC (BIIB), CG ONCOLOGY INC and NUVALENT INC-A (NUVL) stocks. They significantly reduced their stock positions in VERONA PHARMA PLC - ADR (VRNA), EVOLENT HEALTH INC - A (EVH) and REGULUS THERAPEUTICS INC (RGLS). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in SEPTERNA INC, SPDR S&P BIOTECH ETF (BIL) and 10X GENOMICS INC-CLASS A (TXG). The fund showed a lot of confidence in some stocks as they added substantially to SCILEX HOLDING CO, PROTARA THERAPEUTIC INC (TARA) and VOR BIOPHARMA INC (VOR).
RA CAPITAL MANAGEMENT, L.P. Annual Return Estimates Vs S&P 500
Our best estimate is that RA CAPITAL MANAGEMENT, L.P. made a return of -9.3% in the last quarter. In trailing 12 months, it's portfolio return was 4.04%.
New Buys
| Ticker | $ Bought |
|---|---|
| septerna inc | 160,205,000 |
| spdr s&p biotech etf | 110,615,000 |
| 10x genomics inc-class a | 47,092,200 |
| kura oncology inc | 38,768,600 |
| zai lab ltd-adr | 33,917,100 |
| nurix therapeutics inc | 25,120,000 |
| eyepoint pharmaceuticals inc | 23,704,500 |
| ceribell inc | 21,340,200 |
New stocks bought by RA CAPITAL MANAGEMENT, L.P.
Additions
| Ticker | % Inc. |
|---|---|
| scilex holding co | 296 |
| protara therapeutic inc | 78.95 |
| vor biopharma inc | 74.28 |
| cidara therapeutics inc | 55.43 |
| arcellx inc | 50.55 |
| janux therapeutics inc | 13.09 |
| newamsterdam pharma co nv | 9.69 |
| ascendis pharma a/s - adr | 4.14 |
Additions to existing portfolio by RA CAPITAL MANAGEMENT, L.P.
Reductions
| Ticker | % Reduced |
|---|---|
| verona pharma plc - adr | -64.73 |
| evolent health inc - a | -57.99 |
| regulus therapeutics inc | -56.07 |
| bicycle therapeutics plc-adr | -51.47 |
| recursion pharmaceuticals-a | -49.79 |
| bioage labs inc | -40.71 |
| iteos therapeutics inc | -34.3 |
| day one biopharmaceuticals i | -26.88 |
RA CAPITAL MANAGEMENT, L.P. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| tenaya therapeutics inc | -13,476,400 |
| alto neuroscience inc | -23,739,800 |
| an2 therapeutics inc | -2,140,000 |
| cg oncology inc | -52,725,100 |
| adagio medical holdings inc | -3,441,530 |
| metagenomi inc | -2,832,370 |
| biogen inc | -229,595,000 |
| cervomed inc | -11,930,000 |
RA CAPITAL MANAGEMENT, L.P. got rid off the above stocks
Sector Distribution
RA CAPITAL MANAGEMENT, L.P. has about 62% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 62 |
| Others | 36.5 |
| 1.5 |
Market Cap. Distribution
RA CAPITAL MANAGEMENT, L.P. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 39.6 |
| MID-CAP | 33.9 |
| SMALL-CAP | 21.5 |
| MICRO-CAP | 3.5 |
Stocks belong to which Index?
About 51.3% of the stocks held by RA CAPITAL MANAGEMENT, L.P. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 51.3 |
| Others | 48.7 |
RA CAPITAL MANAGEMENT, L.P. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P. has 89 stocks in it's portfolio. About 57.6% of the portfolio is in top 10 stocks. PCVX proved to be the most loss making stock for the portfolio. NAMS was the most profitable stock for RA CAPITAL MANAGEMENT, L.P. last quarter.
Last Reported on: 14 Feb, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABOS | acumen pharmaceuticals inc | 0.34 | 14,932,100 | 25,683,100 | unchanged | 0.00 | ||
| ACET | adicet bio inc | 0.10 | 7,541,000 | 7,254,440 | unchanged | 0.00 | ||
| ACLX | arcellx inc | 2.85 | 2,787,330 | 213,760,000 | added | 50.55 | ||
| ACRS | aclaris therapeutics inc | 0.15 | 4,666,670 | 11,573,300 | new | |||
| ALEC | alector inc | 0.24 | 9,695,230 | 18,324,000 | new | |||
| ALLK | allakos inc | 0.02 | 1,129,930 | 1,367,220 | new | |||
| ANTX | an2 therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARVN | arvinas inc | 0.11 | 421,348 | 8,077,240 | unchanged | 0.00 | ||
| ATXS | astria therapeutics inc | 0.61 | 5,105,210 | 45,640,600 | unchanged | 0.00 | ||
| AVTE | aerovate therapeutics inc | 0.32 | 9,192,090 | 24,359,000 | unchanged | 0.00 | ||
| AVTX | avalo therapeutics inc | 0.10 | 967,000 | 7,184,810 | unchanged | 0.00 | ||
| AXSM | axsome therapeutics inc | 1.13 | 1,000,000 | 84,610,000 | unchanged | 0.00 | ||
| BCYC | bicycle therapeutics plc-adr | 0.20 | 1,093,480 | 15,308,700 | reduced | -51.47 | ||
| BIIB | biogen inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BIL | spdr s&p biotech etf | 1.47 | 1,228,240 | 110,615,000 | new | |||
| CCCC | c4 therapeutics inc | 0.23 | 4,878,000 | 17,560,800 | unchanged | 0.00 | ||
| CDTX | cidara therapeutics inc | 0.39 | 1,092,800 | 29,374,400 | added | 55.43 | ||
| CMRX | chimerix inc | 0.41 | 8,800,000 | 30,624,000 | unchanged | 0.00 | ||
| DAWN | day one biopharmaceuticals i | 0.97 | 5,755,580 | 72,923,200 | reduced | -26.88 | ||
| DYN | dyne therapeutics inc | 2.00 | 6,381,140 | 150,340,000 | unchanged | 0.00 | ||